Close Menu

NEW YORK ─ Eurofins on Thursday said its third quarter revenues increased 17 percent year over year to €1.4 million ($1.7 million) compared to €1.2 million in Q3 2019.

Organic growth was 22.7 percent, the Luxembourg-based company said.

Eurofins core business, excluding any COVID-19 clinical testing and reagents revenues, returned to "small positive organic growth in Q3 2020," the firm said in a statement, adding many of its core businesses ─ including food, environment, and biopharma testing ─ achieved greater than 5 percent organic growth in Q3 2020.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Harvard-led team reprogrammed DNA methylation patterns of mice with eye problems to restore their sight, AFP reports.

A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.

The New York Times reports Moderna is planning a clinical trial of its SARS-CoV-2 vaccine in children.

In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.